SAN DIEGO–(BUSINESS WIRE)–iXCells Biotechnologies (“iXCells” or the “Company”), a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell (“iPSC”) derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners (“GPP”), a private investment firm focusing on the healthcare industry. “iXCells is delighted
Click here to view original post
Copyright © 2022 Biotech Networks, LLC
